Crohn's disease (CD) is a long-lasting condition that causes serious swelling in the digestive tract, especially the bowels. It can lead to tummy pain, diarrhea, feeling tired, and losing weight. This study looks at how safe and effective a medicine called risankizumab is for adults with moderate to severe CD. Risankizumab is an approved drug for treating CD. Participants in this study will go through three periods: A, B, and C. In Period A, they will get either risankizumab or a placebo (a fake treatment) through shots under the skin. The medicine will be given for up to 24 weeks in Periods A and B, and for 52 weeks in Period C, making the total study almost 93 weeks long. About 276 adults from around 250 places worldwide will be part of this study.
- The study is almost 93 weeks long.
- You may receive treatment or a placebo initially.
- You must have tried other CD treatments before joining.